Twinstrand Therapeutics Announces Award Of $2.2 M CDN Research Contract By The US Department Of Defense For Development Of A Medical Countermeasure To Ricin

BURNABY, BC, Sept. 12 /CNW/ - Twinstrand Therapeutics announced today that it has been awarded a contract for research and development of a human polyclonal antibody (antidote) to ricin poisoning. The two-year $2.2 M CDN ($1.9 M USD) contract was granted, in a competitive process, by the United States Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense.